172 related articles for article (PubMed ID: 10541865)
1. Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2B (p15) gene inactivation in malignant gliomas.
Simon M; Köster G; Menon AG; Schramm J
Acta Neuropathol; 1999 Nov; 98(5):444-52. PubMed ID: 10541865
[TBL] [Abstract][Full Text] [Related]
2. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
3. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
4. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
[TBL] [Abstract][Full Text] [Related]
5. High Positive Correlations between
Drak Alsibai K; Vacher S; Meseure D; Nicolas A; Lae M; Schnitzler A; Chemlali W; Cros J; Longchampt E; Cacheux W; Pignot G; Callens C; Pasmant E; Allory Y; Bieche I
Noncoding RNA; 2019 Aug; 5(3):. PubMed ID: 31438464
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors.
Endo M; Kobayashi C; Setsu N; Takahashi Y; Kohashi K; Yamamoto H; Tamiya S; Matsuda S; Iwamoto Y; Tsuneyoshi M; Oda Y
Clin Cancer Res; 2011 Jun; 17(11):3771-82. PubMed ID: 21262917
[TBL] [Abstract][Full Text] [Related]
7. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
8. Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas.
Labuhn M; Jones G; Speel EJ; Maier D; Zweifel C; Gratzl O; Van Meir EG; Hegi ME; Merlo A
Oncogene; 2001 Mar; 20(9):1103-9. PubMed ID: 11314047
[TBL] [Abstract][Full Text] [Related]
9. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
10. Expression of Chr9p21 genes CDKN2B (p15(INK4b)), CDKN2A (p16(INK4a), p14(ARF)) and MTAP in human atherosclerotic plaque.
Holdt LM; Sass K; Gäbel G; Bergert H; Thiery J; Teupser D
Atherosclerosis; 2011 Feb; 214(2):264-70. PubMed ID: 20637465
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours.
Rousseau E; Ruchoux MM; Scaravilli F; Chapon F; Vinchon M; De Smet C; Godfraind C; Vikkula M
Neuropathol Appl Neurobiol; 2003 Dec; 29(6):574-83. PubMed ID: 14636164
[TBL] [Abstract][Full Text] [Related]
12. Preferentially different mechanisms of inactivation of 9p21 gene cluster in liver fluke-related cholangiocarcinoma.
Chinnasri P; Pairojkul C; Jearanaikoon P; Sripa B; Bhudhisawasdi V; Tantimavanich S; Limpaiboon T
Hum Pathol; 2009 Jun; 40(6):817-26. PubMed ID: 19200577
[TBL] [Abstract][Full Text] [Related]
13. p16 is a major inactivation target in hepatocellular carcinoma.
Jin M; Piao Z; Kim NG; Park C; Shin EC; Park JH; Jung HJ; Kim CG; Kim H
Cancer; 2000 Jul; 89(1):60-8. PubMed ID: 10897001
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.
Faderl S; Kantarjian HM; Estey E; Manshouri T; Chan CY; Rahman Elsaied A; Kornblau SM; Cortes J; Thomas DA; Pierce S; Keating MJ; Estrov Z; Albitar M
Cancer; 2000 Nov; 89(9):1976-82. PubMed ID: 11064355
[TBL] [Abstract][Full Text] [Related]
15. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
16. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.
Peng CY; Chen TC; Hung SP; Chen MF; Yeh CT; Tsai SL; Chu CM; Liaw YF
Anticancer Res; 2002; 22(2B):1265-71. PubMed ID: 12168936
[TBL] [Abstract][Full Text] [Related]
17. Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma.
Tachibana I; Smith JS; Sato K; Hosek SM; Kimmel DW; Jenkins RB
Am J Med Genet; 2000 May; 92(2):136-41. PubMed ID: 10797439
[TBL] [Abstract][Full Text] [Related]
18. Deregulation of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in basal cell carcinoma.
Kanellou P; Zaravinos A; Zioga M; Spandidos DA
Br J Dermatol; 2009 Jun; 160(6):1215-21. PubMed ID: 19298278
[TBL] [Abstract][Full Text] [Related]
19. Alternative splicing of the p15 cdk inhibitor in glioblastoma multiforme.
Simon M; Köster G; Ludwig M; Mahlberg R; Rho S; Watzka M; Schramm J
Acta Neuropathol; 2001 Aug; 102(2):167-74. PubMed ID: 11563632
[TBL] [Abstract][Full Text] [Related]
20. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.
Randerson-Moor JA; Harland M; Williams S; Cuthbert-Heavens D; Sheridan E; Aveyard J; Sibley K; Whitaker L; Knowles M; Bishop JN; Bishop DT
Hum Mol Genet; 2001 Jan; 10(1):55-62. PubMed ID: 11136714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
